Skip to main content

Bevacizumab Dosage

Medically reviewed by Drugs.com. Last updated on Jun 30, 2023.

Applies to the following strengths: bvzr 25 mg/mL; 25 mg/mL; awwb 25 mg/mL; maly 25 mg/mL; adcd 25 mg/mL

Usual Adult Dose for Colorectal Cancer

In combination with bolus-IFL: 5 mg/kg IV every 2 weeks
In combination with FOLFOX4: 10 mg/kg IV every 2 weeks
In combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line bevacizumab-containing regimen: 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks

Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use:

Usual Adult Dose for Non-Small Cell Lung Cancer

In combination with carboplatin and paclitaxel: 15 mg/kg IV every 3 weeks

Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: For first-line therapy of unresectable, locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel

Usual Adult Dose for Glioblastoma Multiforme

10 mg/kg IV every 2 weeks

Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: For the treatment of recurrent glioblastoma in adults

Usual Adult Dose for Renal Cell Carcinoma

In combination with interferon alfa: 10 mg/kg IV every 2 weeks

Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: For metastatic renal cell carcinoma in combination with interferon alfa

Usual Adult Dose for Cervical Cancer

In combination with paclitaxel and cisplatin OR paclitaxel and topotecan: 15 mg/kg IV every 3 weeks

Comments:


Use: For persistent, recurrent, or metastatic carcinoma of the cervix in combination with paclitaxel and cisplatin or paclitaxel and topotecan

Usual Adult Dose for Ovarian Cancer

TREATMENT OF STAGE III OR IV DISEASE FOLLOWING INITIAL SURGICAL RESECTION:
15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by bevacizumab 15 mg/kg IV every 3 weeks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs earlier

TREATMENT OF RECURRENT DISEASE:
PLATINUM RESISTANT:
10 mg/kg IV every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan (every week)

PLATINUM SENSITIVE:

Comments:

Uses:

Usual Adult Dose for Fallopian Tube Cancer

TREATMENT OF STAGE III OR IV DISEASE FOLLOWING INITIAL SURGICAL RESECTION:
15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by bevacizumab 15 mg/kg IV every 3 weeks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs earlier

TREATMENT OF RECURRENT DISEASE:
PLATINUM RESISTANT:
10 mg/kg IV every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan (every week)

PLATINUM SENSITIVE:

Comments:

Uses:

Usual Adult Dose for Peritoneal Cancer

TREATMENT OF STAGE III OR IV DISEASE FOLLOWING INITIAL SURGICAL RESECTION:
15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by bevacizumab 15 mg/kg IV every 3 weeks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs earlier

TREATMENT OF RECURRENT DISEASE:
PLATINUM RESISTANT:
10 mg/kg IV every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan (every week)

PLATINUM SENSITIVE:

Comments:

Uses:

Usual Adult Dose for Hepatocellular Carcinoma

15 mg/kg IV (after administration of atezolizumab 1200 mg IV on the same day) every 3 weeks until disease progression or unacceptable toxicity

Comments:


Use: In combination with atezolizumab for patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

No dose reductions are recommended for this drug.

If proteinuria develops and is greater than or equal to 2 grams per 24 hours in absence of nephrotic syndrome: Withhold this drug until proteinuria is less than 2 grams per 24 hours.

If wound healing complications of any grade develop: Withhold this drug until adequate wound healing; the safety of resumption after resolution of wound healing complications has not been established.

If a clinically significant infusion reaction occurs that is not severe: Interrupt the infusion and resume at a decreased rate after symptoms resolve.

Discontinue this drug for any of the following:

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


General:

Monitoring:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.